Carisma Therapeutics Inc. Logo

Carisma Therapeutics Inc.

Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.

CARM | US

Overview

Corporate Details

ISIN(s):
US14216R1014 (+2 more)
LEI:
Country:
United States of America
Address:
3675 MARKET STREET, 19104 PHILADELPHIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of engineered cell therapies. The company utilizes its proprietary macrophage and monocyte cell engineering platform to create first-in-class Chimeric Antigen Receptor Macrophage (CAR-M) therapeutics. These therapies are designed to leverage the unique abilities of macrophages to infiltrate solid tumors, directly kill cancer cells via targeted phagocytosis, and activate a broad anti-tumor immune response. Carisma is building a pipeline of programs focused on treating serious disorders, including solid tumors, fibrosis, and autoimmune diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Carisma Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carisma Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carisma Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SINOVAC BIOTECH LTD Logo
Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.
United States of America
SVA
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America
SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea
326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea
302440
Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America
SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway
SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan
4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America
SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America
SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB

Talk to a Data Expert

Have a question? We'll get back to you promptly.